HC Wainwright Has Positive Estimate for Heatwurx Q2 Earnings

Heatwurx Inc. (NASDAQ:PCSA) – HC Wainwright upped their Q2 2025 earnings per share estimates for shares of Heatwurx in a research note issued to investors on Monday, June 30th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.23) per share for the quarter, up from their prior estimate of ($0.65). HC Wainwright has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Heatwurx’s current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for Heatwurx’s Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.54) EPS.

Heatwurx (NASDAQ:PCSA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.47.

Heatwurx Stock Performance

Shares of Heatwurx stock opened at $0.19 on Wednesday. Heatwurx has a fifty-two week low of $0.15 and a fifty-two week high of $3.10. The stock has a 50 day moving average of $0.26 and a 200 day moving average of $0.47. The firm has a market capitalization of $2.24 million, a price-to-earnings ratio of -0.06 and a beta of 1.30.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.